

# Treatment with INGREZZA<sup>®</sup> (valbenazine) capsules: Patient Case Reviews

This promotional educational activity is sponsored by Neurocrine Biosciences, Inc. and is not certified for CME credit. The speaker is a paid consultant of Neurocrine and the information presented will be consistent with FDA guidelines.

## PRESENTED BY

Kent McDaniel, MD

Neuropsychiatrist  
Department of Psychiatry  
Henrico Area Mental Health Services  
Henrico, VA

## DATE/TIME

Wednesday, 8/4/2021 6:30 PM Pacific

## LOCATION

The Davenport Grand  
333 West Spokane Falls Boulevard  
Spokane WA 99201

**Please RSVP to your Neurocrine Representative, Ben Slabaugh at [bslabaugh@neurocrine.com](mailto:bslabaugh@neurocrine.com) or (208) 610-4236 by 7/30/2021.**

*Ensuring the health and well-being of customers remains Neurocrine's highest priority and as such please refrain from attending a live program if you have experienced any of the following symptoms in the last 48 hours: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, been in close contact with a person with symptomatic laboratory confirmed COVID-19. Additionally please follow guidelines set forth by state and local agencies and the Centers for Disease Control and Prevention.*

## INDICATION & USAGE

INGREZZA<sup>®</sup> (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA.

Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

Please see Important Safety Information continued on the following page.

Please see INGREZZA full [Prescribing Information](#).

## WARNINGS & PRECAUTIONS

### Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

### QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

### Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

## ADVERSE REACTIONS

The most common adverse reaction ( $\geq 5\%$  and twice the rate of placebo) is somnolence. Other adverse reactions ( $\geq 2\%$  and  $>$ Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please [see](#) attached INGREZZA full Prescribing Information or visit [www.INGREZZAHCP.com/PI](http://www.INGREZZAHCP.com/PI).

Pursuant to Neurocrine policy, an HCP should attend no more than three out-of-office Peer-to-Peer Speaker Programs accompanied by a meal per calendar year, irrespective of the topic. Of the three out-of-office Peer-to-Peer Speaker Programs an HCP attends, an HCP may attend up to two programs on the same topic, i.e., a particular Neurocrine product or a particular disease state.

As required by the U.S. Sunshine Act, Neurocrine will track and report to government agencies the cost of meals provided to individual health care professionals in connection with attendance at this promotional educational activity. This information will be made publicly available. If you wish to not partake in the meal, please "opt out" of the meal when signing in.